$ cat ./records/gates-foundation-commits-1-6-billion-to-gavi-2021-2025-strategy-a-2020.txt
Gates Foundation Commits $1.6 Billion to Gavi 2021–2025 Strategy at Global Vaccine Summit
[RECORD.TXT] · cat --full
At the UK-hosted Global Vaccine Summit in June 2020, the Gates Foundation committed $1.6 billion to Gavi's 2021–2025 strategic period, pushing cumulative foundation Gavi contributions past $4 billion. The strategy targets immunising 300 million additional children and averting 7–8 million deaths. Funding supports Gavi's digital immunisation data systems and work with African regional manufacturers to build resilient local vaccine supply chains. The summit overall raised $8.8 billion, exceeding the $7.4 billion target.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Grants EcoHealth Alliance $1.5 Million to Build India's National One Health Platform for Zoonotic Disease
Next →
Gates Foundation Co-Sponsors WHO Defeating Meningitis by 2030 Roadmap Targeting 50% Case Reduction
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.